Suchergebnisse - "Downey, Louise"

PubPharm (6)

1

Treatment of age-related macular degeneration with aflibercept using a treat, extend and fixed protocol; A 4-year study of treatment outcomes, durability, safety and quality of life (An extension to the MATE randomised controlled trial)

enthalten in: Acta ophthalmologica | 2024

von Airody, A. | Baseler, H. | Seymour, J. | +12

2

Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE) : two randomised, double-masked, phase 3, non-inferiority trials

enthalten in: Lancet (London, England) | 2022

von Heier, J. | Khanani, A. | Quezada Ruiz, C. | +115

CommentIn: Lancet. 2022 Feb 19;399(10326):697-699. - PMID 35085501

3

Recommendations by a UK expert panel on an aflibercept treat-and-extend pathway for the treatment of neovascular age-related macular degeneration

enthalten in: Eye (London, England) | 2020

von Ross, A. | Downey, L. | Devonport, H. | +8

4

Secondary End Points in the RIVAL Study

enthalten in: JAMA ophthalmology | 2019

von McKibbin, M. | Downey, L.

CommentOn: JAMA Ophthalmol. 2019 Apr 1;137(4):372-379. - PMID 30676617

5

VISUAL ACUITY IMPROVEMENT WHEN SWITCHING FROM RANIBIZUMAB TO AFLIBERCEPT IS NOT SUSTAINED

enthalten in: Retina (Philadelphia, Pa.) | 2018

von Lee, C. | Kim, A. | Baughman, D. | +12

6

UK AMD/DR EMR REPORT IX : comparative effectiveness of predominantly as needed (PRN) ranibizumab versus continuous aflibercept in UK clinical practice

enthalten in: The British journal of ophthalmology | 2017

von Lee, A. | Lee, C. | Egan, C. | +11

1
[1]